Rafael Ortiz, MD
Ophthalmology · Miami, FLNPI 1225186067
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 36.7% of the total. Reporting peaked in 2019 at $449 and has fallen 51.6% since, to $217 in 2025. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.
Across 64 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$512
- Aerie Pharmaceuticals, Inc.$219
- Astellas Pharma US Inc$149
- Novartis$101
- Apellis Pharmaceuticals, Inc.$101
- Sun Pharmaceutical Industries Inc.$94
- plus $219 from 8 others
Across 23 payments — averaging $4673.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$106K
- AbbVie$2K
What the payments were for
- Food & beverage$1,395100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $512 |
| Aerie Pharmaceuticals, Inc. | 11 | $219 |
| Astellas Pharma US Inc | 6 | $149 |
| Novartis | 5 | $101 |
| Apellis Pharmaceuticals, Inc. | 4 | $101 |
| Sun Pharmaceutical Industries Inc. | 4 | $94 |
| Alcon | 2 | $46 |
| Dompe US, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Thea Pharma Inc. | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Akorn, Inc. | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
How this compares
$1,395 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 62 | $63,396 |
| RhopressaNetarsudil Mesylate | 93 | $45,060 |
| VyzultaLatanoprostene Bunod | 115 | $40,745 |
| LumiganBimatoprost | 39 | $26,788 |
| XiidraLifitegrast | 16 | $13,804 |
| Cyclosporine | 30 | $10,430 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $5,576 |
| Azelastine Hcl | 159 | $5,129 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $5,006 |
| Brimonidine Tartrate | 95 | $3,589 |
| Ketorolac Tromethamine | 81 | $2,152 |
| Latanoprost | 197 | $1,926 |
| Dorzolamide Hcl | 92 | $1,737 |
| Timolol Maleate | 53 | $725 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $512 | $90,183101 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $24 | $54,548131 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $219 | $45,06093 claims |
| AlconSimbrinza | $46 | $5,00622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- William TrattlerMiami$579K
- Jennifer LohMiami$545K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$349K
- Jaclyn KovachMiami$333K
- Andrew SchimelMiami$320K
- Carlos BuznegoMiami$287K
- Felipe MedeirosMiami$266K
- Michael YimMiami$161K
- Arnulfo MansurMiami$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.